Jakob Dupont - Mar 1, 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role: EVP, Head of R&D
Signature: /s/ Jeff Kiekhofer, Attorney-in-Fact for Jakob Dupont
Stock symbol: ATRA
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/3/2023, 04:15 PM
Previous filing: Nov 18, 2022
Next filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRA	Common Stock	Award	$0	+141K	+91.45%	$0.00	296K	Mar 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATRA	Employee Stock Option (Right to Buy)	Award	$0	+318K		$0.00	318K	Mar 1, 2023	Common Stock	318K	$3.91	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. "Company Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year.
F2	1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service.